Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Gene Therapy C-elegans-deletion-mutants

 Water treatment apparatus
The embodiments of the invention in which an exclusive property or privilege is claimed are defined ...


 Membrane cell
What we claim is: 1. A monopolar filter press electrolytic cell suitable for use in the ...


 Encapsulating biological active substances into erythrocytes
We claim: 1. A process for the encapsulation in human or animal erythrocytes of at least one ...


 Flow chamber and electro-manipulator incorporating same
Accordingly, an object of the present invention is to provide a flow chamber and an electro-...


 Electroblotting technique for transferring specimens from a polyacrylamide electrophoresis or like gel onto a membrane
What is claimed is: 1. An apparatus especially suitable for transferring a biological specimen from ...


 Probe for electrofusion, electroporation, or like procedure
The present invention provides a structure and method for treating samples in a well tray. Briefly, ...


 Device and method for the electrophoretic separation of macromolecules
The invention relates to an electrophoresis device and an electrophoresis method for the separation ...


 Superfusion apparatus
It is an object of the present invention to provide a superfusion apparatus for use in receptor ...


 Method and apparatus for administration of anticoagulant to red cell suspension output of a blood separator
OF THE PREFERRED EMBODIMENTS Referring now to the drawings, particularly to FIG. 1, there is ...


 Electroporation device
I claim: 1. An electroporation apparatus for electroporating living cells with molecules comprising:...


 C. elegans deletion mutants

Details
Inventors: Johnson, Carl; Westlund, Bethany; Parry, Dianne;
Assignee: Axys Pharmaceuticals, Inc. (South San Francisco, CA)
Primary Examiner: Clark; Deborah J. R.
Assistant Examiner: Baker; Anne-Marie
Attorney, Agent or Firm: Clark & Elbing LLP, Bieker-Brady; Kristina

Provided are worms having deletions in genes associated with Alzheimer's disease and methods for detecting genes and compounds involved in the causation of Alzheimer's disease or useful for the treatment of Alzheimer's disease. A novel method for constructing deletions in the nematode is also provided.

DETAILED DESCRIPTION What is claimed is: 1.
A nematode having null mutations in hop-1 and sel-12, said nematode having a combined maternal-effect embryonic lethality and egg laying defective phenotype, at least one of said mutations being introduced by artifice, wherein said nematode is a C.
elegans nematode.




Description:
BACKGROUND OF THE INVENTION The field of the invention is Alzheimer's disease.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system involving loss of memory and cognitive function.
Neuropathological hallmarks of AD extracellular amyloid plaques, whose major component is the A.
beta.
peptide, a proteolytic product of the .
beta.
-amyloid precursor protein (APP).
Dominant mutations in any of three mammalian genes, PS1, PS2, and APP are causative for the early-onset, familial form of AD (FAD).
PS1 and PS2 encode related proteins-, while APP encodes the amyloid precursor protein (APP) (reviewed in Hardy, Trends Neurosci.
20:154-159, 1997), from which the A.
beta.
peptide is generated by proteolytic processing.
Since presenilin-1 (PS1) and presenilin-2 (PS2) were first identified as genes mutated in FAD, much effort has been devoted to elucidating the biological function of presenilins in normal and disease states.
Two lines of evidence support a hypothesis that presenilins affect proteolytic processing of APP First, PS(FAD) mutations are associated with an increase in a longer, more amyloidogenic form of A.
beta.
known as A.
beta.
42 ; and second, levels of A.
beta.
are decreased several-fold in neurons derived from PS1 knockout mice relative to PS1(+) control mice.
Moreover, in neurons, A.
beta.
42 may be generated in the endoplasmic reticulum, where presenilins have been localized.
C.
elegans has three presenilin genes, spe-4 (spermatogenesis defective) (L'Hernault, et al.
, J.
Cell Biol.
, 119:55-68, 1992), sel-12 (suppressor and/or enhancer of lin-12) (Levitan et al.
, Nature 377:351-354, 1995), and hop-1 (homolog of presenilin) (Li et al



Related patents
  Feline hepatocyte growth factor
The invention claimed is: 1. An isolated DNA or RNA encoding a protein having an amino acid sequence as shown in SEQ ID NO: 2 or SEQ ID NO: 4. 2. A recombinant vector ...
  ppRB.sup.110 -phosphoprotein the retinoblastoma susceptibility gene product
OF FIGURES FIG. 1 is the chromatogram illustrating the identification of RB proteins by immunoprecipitation with rabbit anti-RB IgG in various cell lines. Human cells ...
  Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
It has now been discovered that tumor formation in a patient can be treated or prevented by administering to the patient an antigen-presenting cell(s) that is loaded ...
  Mutants of the RB and P53 genes
OF THE INVENTION Definitions The term "functional expression of the gene" meant to include the suppression of transcription of the gene, the degradation of the gene ...
  Oncolytic virus therapy
OF THE INVENTION As used herein the term "human cells" means cells isolated from a human, or cultured cells that have been derived from cells isolated from a human and/...
  Covalently cross-linked oligonucleotides
OF THE INVENTION In accordance with the objects of this invention novel, covalently cross-linked oligonucleotide strands are disclosed. Preferably such strands are "...
  Methods of inducing cancer cell death and tumor regression
The present invention provides methods of treating cancer in a patient (e.g., a mammal such as a human) in need of such treatment, comprising administering an effective ...
  Injectable hyaluronic acid derivative with pharmaceuticals/cells
OF THE INVENTION The present invention concerns injectable, biocompatible and biodegradable compositions containing at least one hyaluronic acid benzyl ester derivative ...
  Modification of polymer surfaces and molecular immobilization by photoreaction
OF THE INVENTION To obviate disadvantages associated with the modification methods presently existing, the object of the present invention is to provide a method for ...
  Wound and skin care compositions
What is claimed: 1. A composition comprising a dermatologically acceptable carrier and an effective amount of a hydroxy acid compound, present in a concentration of ...

0.014

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved